Butaprost
Based on 2 publication(s) in Google Scholar
Butaprost is a selective prostaglandin E receptor (EP2) agonist with an EC50 of 33 nM and a Ki of 2.4 μM for murine EP2 receptor. Butaprost is less activity against murine EP1, EP3 and EP4 receptors. Butaprost attenuates fibrosis by hampering TGF-β/Smad2 signalling.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.85%
- CAS 番号: 69685-22-9
- 分子式: C24H40O5
- 分子量:408.57
-
保管条件:
Solution, -20°C, 2 years
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Butaprost
More
生物活性
Butaprost (1-100 nM; 0.5-24 hours) induces about a five-fold upregulation of Nur77 mRNA expression in hEP2-HEK293/EBNA cells in a dose- and time-dependent. Butaprost upregulated Nur77 gene expression through the PKC pathway[1].
Butaprost (50 μM; 24 hours) reduces TGF-β-induced fibronectin (FN) expression, Smad2 phosphorylation and epithelial-mesenchymal transition in Madin-Darby Canine Kidney (MDCK) cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK 293/EBNA cells stably expressing the human EP2 receptor (hEP2-HEK 293/EBNA cells)
-
Concentration:1 nM, 10 nM, 100 nM
-
Incubation Time:0.5 hours, 1 hours, 6 hours, 24 hours
-
Result:Induced about a five-fold upregulation of Nur77 mRNA expression in hEP2-HEK293/EBNA cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6 mice (8 weeks of age; 21 g) bearing unilateral ureteral obstruction surgery[2]
-
Dosage:1 mg/kg, 2 mg/kg, 4 mg/kg
-
Administration:Intraperitoneal injection; twice daily; for 7 days
-
Result:Attenuated the development of fibrosis in mice that underwent unilateral ureteral obstruction surgery.
化学情報
-
CAS 番号 69685-22-9
-
性状 Liquid
-
分子量 408.57
-
分子式 C24H40O5
-
Color Colorless to light yellow
-
SMILES
COC(CCCCCC[C@@H](C(C[C@H]1O)=O)[C@H]1/C=C/C[C@@H](C2(CCC2)CCC)O)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Solution, -20°C, 2 years
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Neuroinflammation
Taprenepag restores maternal-fetal interface homeostasis for the treatment of neurodevelopmental disorders. [Abstract]2024 Nov 28;21(1):307. PMID: 39609821 -
純度とドキュメンテーション
-
データシート (275 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Yanbin Liang, et al. Upregulation of orphan nuclear receptor Nur77 following PGF(2alpha), Bimatoprost, and Butaprost treatments. Essential role of a protein kinase C pathway involved in EP(2) receptor activated Nur77 gene transcription. Br J Pharmacol. 2004 Jun;142(4):737-48. [Content Brief]
[2]. Michael Schou Jensen, et al. Activation of the prostaglandin E 2 EP 2 receptor attenuates renal fibrosis in unilateral ureteral obstructed mice and human kidney slices. Acta Physiol (Oxf). 2019 Sep;227(1):e13291. [Content Brief]
[3]. K Tani, et al. Design and synthesis of a highly selective EP2-receptor agonist. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2025-8. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Powered by Bioz